Related Experiment Video
Updated: May 29, 2026
14:24
Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
Published on: January 21, 2018
Interventional treatments for hypertrophic cardiomyopathy
Saidi A Mohiddin1, Charles Knight
1The Heart Muscle Disease Clinic, London Chest Hospital, Barts and The London NHS Trust, London, UK. smohiddin@doctors.org.uk
Cardiovascular Therapeutics
|September 3, 2011
Summary
Hypertrophic cardiomyopathy (HCM), an inherited heart condition, can cause severe symptoms and risks. This review focuses on interventional treatments for managing left ventricular outflow tract obstruction (LVOTO) in HCM patients.
Area of Science:
- Cardiology
- Genetics
- Internal Medicine
Background:
- Hypertrophic cardiomyopathy (HCM) is the most prevalent inherited cardiac disorder.
- It is characterized by left ventricular hypertrophy, potentially leading to functional limitations and premature death.
- While many patients remain asymptomatic, severe symptoms and risks like arrhythmia and heart failure can arise.
Purpose of the Study:
- To describe interventional treatments for severe symptoms in hypertrophic cardiomyopathy.
- Focus on managing left ventricular outflow tract obstruction (LVOTO).
Main Methods:
- Review of clinical management strategies for HCM.
- Focus on interventional treatments for symptomatic LVOTO.
Main Results:
- Clinical management includes genetic counseling, prognostic risk assessment, and symptom management.
- Interventional treatments are key for severe symptoms related to LVOTO.
Conclusions:
- Effective management of HCM involves a multi-faceted approach.
- Interventional therapies are crucial for addressing severe symptoms and improving outcomes in patients with LVOTO.
Related Concept Videos
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...